Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...
Explore how community oncology reduces financial toxicity in cancer care, highlighting cost savings and quality benefits over ...
Lung cancer incidence rates in the United States have undergone a significant transformation over the last several decades, ...
Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% reduction in progression or death. The MajesTEC-9 trial highlights ...
Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...
The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
Explore how community oncology reduces financial toxicity in cancer care, highlighting cost savings and quality benefits over ...
The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...
Findings from a phase I trial (NCT04183166) evaluating TG4050, a neoantigen therapeutic vaccine, in patients with operable, ...
In July 2025, a class 2 resubmission of tab-cel’s BLA was initiated by Atara Biotherapeutics, developer and sponsor of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback